Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Clinical Trial
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
The study sponsor, Ra Pharma, is developing an investigational drug, zilucoplan, for treatment of people with gneralized myasthenia gravis, or gMG. gMG is caused when your immune system attacks part of your muscle and prevents the nerve signal from getting through. Zilucoplan is designed to prevent the immune system from attacking your muscles. The main purpose of this study is to test whether zilucoplan works and is safe for people with gMG. Participation in this study can continue until zilucoplan is approved and available in your country or until the Sponsor stops development of zilucoplan for gMG.
Eligibility Criteria
- Inclusion Criteria: Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study Exclusion Criteria: With the exception of a prior zilucoplan trial, participation in another clinical trial involving an experimental drug (participation in observational studies and/or registry studies is permitted) Any new or worsening medical condition (since entry into the qualifying zilucoplan study) or any other reason that, in the opinion of the investigator or Sponsor, would disqualify you from participation in this study
RESEARCH. INNOVATION. DISCOVERY.